Calcium-dependent phosphodiesterase 1C inhibits renin release from isolated juxtaglomerular cells.
Renin release from the juxtaglomerular (JG) cell is stimulated by the second messenger cAMP and inhibited by calcium. We previously showed JG cells contain a calcium sensing receptor (CaSR), which, when stimulated, decreases cAMP formation and inhibits renin release. We hypothesize CaSR activation decreases cAMP and renin release, in part, by stimulating a calcium calmodulin-activated phosphodiesterase 1 (PDE1). We incubated our primary culture of JG cells with two selective PDE1 inhibitors [8-methoxymethil-IBMX (8-MM-IBMX; 20 microM) and vinpocetine (40 microM)] and the calmodulin inhibitor W-7 (10 microM) and measured cAMP and renin release. Stimulation of the JG cell CaSR with the calcimimetic cinacalcet (1 microM) resulted in decreased cAMP from a basal of 1.13 +/- 0.14 to 0.69 +/- 0.08 pM/mg protein (P < 0.001) and in renin release from 0.89 +/- 0.16 to 0.38 +/- 0.08 microg ANG I/mlxh(-1)xmg protein(-1) (P < 0.001). However, the addition of 8-MM-IBMX with cinacalcet returned both cAMP (1.10 +/- 0.19 pM/mg protein) and renin (0.57 +/- 0.16 microg ANG I/mlxh(-1)xmg protein(-1)) to basal levels. Similar results were obtained with vinpocetine, and also with W-7. Combining 8-MM-IBMX and W-7 had no additive effect. To determine which PDE1 isoform is involved, we performed Western blot analysis for PDE1A, B, and C. Only Western blot analysis for PDE1C showed a characteristic band apparent at 80 kDa. Immunofluorescence showed cytoplasmic distribution of PDE1C and renin in the JG cells. In conclusion, PDE1C is expressed in isolated JG cells, and contributes to calcium's inhibitory modulation of renin release from JG cells.
Ortiz-Capisano
M Cecilia
MC
Department of Medicine, Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Michigan 48202, USA.
Liao
Tang-Dong
TD
Ortiz
Pablo A
PA
Beierwaltes
William H
WH
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D002147:Calmodulin / Q000037:antagonists & inhibitors; D002478:Cells, Cultured; D000069449:Cinacalcet; D000242:Cyclic AMP / Q000378:metabolism; D054677:Cyclic Nucleotide Phosphodiesterases, Type 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007606:Juxtaglomerular Apparatus / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009281:Naphthalenes / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D044169:Receptors, Calcium-Sensing / Q000378:metabolism; D012083:Renin / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology; D014748:Vinca Alkaloids / Q000494:pharmacology
D002147:Calmodulin; D009281:Naphthalenes; D010726:Phosphodiesterase Inhibitors; D044169:Receptors, Calcium-Sensing; D013449:Sulfonamides; D014748:Vinca Alkaloids; C013983:vinpocetine; C017967:W 7; D000242:Cyclic AMP; D054677:Cyclic Nucleotide Phosphodiesterases, Type 1; C517273:Pde1C protein, mouse; D012083:Renin; D015056:1-Methyl-3-isobutylxanthine; D000069449:Cinacalcet